Incyte Pharmaceuticals, Inc.

Incyte Genomics, Inc.

Incyte Corporation

Other

Telefonaktiebolaget Lm Ericsson (publ)

Incyte Pharmaceuticles, Inc.

Incyte Pharamceuticals, Inc.

Purvi Shah

Neil C Corley

Jennifer L Hillman

Preeti G Lal

Olga Bandman

Karl J Guegler

Henry Yue

Y Tom Tang

Lynn E Murry

Surya K Goli

Janice K Au-Young

Kunal Pankaj Shah

Phillip R Hawkins

Chandra Patterson

Ingrid E Akerblom

Tom Y Tang

Jeffrey J Seilhamer

Susan G Stuart

Matthew R Kaser

David Gray Streeter

Tod M Klingler

Angelo M Delegeane

Richard D Goold

Joanne R Petithory

John Volkering

Laith Said

Christina M Altus

Neil C Gorley

Steve E Lincoln

Wendy B Levine

Samuel T LaBrie

Daniel Derksen

Pretti Lal

A barrier layer is disposed on a copper surface, the barrier layer including an organic molecule. The organic molecule may be a nitrogen-containing molecule. The nitrogen-containing organic molecule includes 1 to 6 carbon atoms. The barrier layer may be deposited on an exposed copper surface before deposition of a surface finish.

Barrier layer

A surface finish for a printed circuit board (PCB) and semiconductor wafer includes a nickel disposed over an aluminum or copper conductive metal surface. A barrier layer including all or fractions of a nitrogen-containing molecule is deposited on the surface of the nickel layer to make a barrier layer/electroless nickel (BLEN) surface finish. The barrier layer allows solder to be reflowed over the surface finish. Optionally, gold (e.g., immersion gold) may be coated over the barrier layer to create a nickel/barrier layer/gold (NBG) surface treatment. Presence of the barrier layer causes the surface treatment to be smoother than a conventional electroless nickel/immersion gold (ENIG) surface finish. Presence of the barrier layer causes a subsequently applied solder joint to be stronger and less subject to brittle failure than conventional ENIG.

Printed circuit surface finish, method of use, and assemblies made therefrom

A method for providing Link Aggregation Control between a plurality of systems adapted for Link Aggregation is provided. The plurality of systems includes a primary system, a first secondary system, and a second secondary system. The primary system comprises first primary ports being linked to first ports of the first secondary system by first links. Further, the primary system comprises second primary ports being linked to second ports of the second secondary system by second links. The method comprises forming a link aggregation group, wherein the link aggregation group includes at least one first link and at least one second link. A preferred system among the secondary systems having links within the link aggregation group is selected and further, the method comprises setting the status of the primary ports according to the selection of the preferred system.

Method and system for link aggregation

The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.

Methods for detecting expression of human protease molecules

The invention provides three human vesicle trafficking proteins (VTP) and polynucleotides which identify and encode VTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of VTP.

Vesicle trafficking proteins

Human protease molecules

The present invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing NHLP and for treating or preventing disorders associated with expression of NHLP.

Human lysophospholipase

The invention provides a human new glutathione S-transferase (GSTS) and polynucleotides which identify and encode GSTS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GS.

Glutathione S-transferase

The invention provides human galactosyltransferases (HUGA) and polynucleotides which identify and encode HUGA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HUGA.

Human galactosyltranferases

The invention provides a cDNA which encodes a TUAN. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of inflammatory and cell proliferative disorders, in particular, Crohn's disease and colon cancer. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.

Tumor-associated antigen

The invention provides a new human cathepsin (LCAP) and polynucleotides which identify and encode LCAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LCAP.

Human cathepsin

The invention provides human hydrolase-like molecules (HHLM) and polynucleotides which identify and encode HHLM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HHLM.

Human hydrolase-like molecules

Growing community of inventors

Sunnyvale, CA, United States of America

Purvi Shah